Glycosmedia Weekly Diabetes News Update
View this email in your browser

Gold Sponsors:

Novo Nordisk

AstraZeneca

Boehringer Ingelheim

Silver Sponsors:

Abbott Diabetes Care

Ascensia Diabetes Care

Ericas

Glycosmedia Weekly Diabetes News - 12/10/2021

Association of thyroid hormone with body fat content and lipid metabolism in euthyroid male patients with type 2 diabetes mellitus: a cross-sectional study

This study found that the changes in thyroid hormones are associated with various body fat content and lipid metabolism in euthyroid male patients with T2DM (BMC Endocrine Disorders)


Associations between serum total bilirubin, obesity and type 2 diabetes

This study suggests that STB is associated with an elevated risk of T2D. More importantly, we reported for the first time that BMI may moderate the association between bilirubin and T2D (Diabetology & Metabolic Syndrome)


Association of diabetes with atrial fibrillation types: a systematic review and meta-analysis

Our findings suggest that diabetes is associated with an increased likelihood of non-paroxysmal AF rather than paroxysmal AF (Cardiovascular Diabetology)


Plasma metabolomic profiling in subclinical atherosclerosis: the Diabetes Heart Study

Strikingly different metabolic signatures were associated with subclinical coronary atherosclerosis in AA and EA DHS participants (Cardiovascular Diabetology)


IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045

Just over half a billion people are living with diabetes worldwide which means that over 10.5% of the world’s adult population now have this condition (IDF)


The use of flash glucose monitoring significantly improves glycemic control in type 2 diabetes managed with basal bolus insulin therapy compared to self-monitoring of blood glucose

HbA1c significantly improved in basal-bolus treated type 2 diabetes after flash glucose monitoring use for 3–6 months compared to SMBG (Diabetes Research and Clinical Practice)


Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Empagliflozin thus ameliorates the “cardiac energy-deficient” state, regresses adverse myocardial cellular remodeling, and improves cardiac function, offering therapeutic opportunities to prevent or modulate HF in T2D (Diabetes)


Current provision and HCP experiences of remote care delivery and diabetes technology training for people with type 1 diabetes in the UK during the Covid-19 pandemic

This survey highlights UK health care professionals experiences of remote care delivery. Whilst supportive of virtual care models, a number of factors highlighted, especially patient digital literacy, need to be addressed to improve virtual care delivery and device training (Diabetic Medicine)


Share
Tweet
Forward
+1
Share
Please visit the Glycosmedia website for more features and information, including:

Journal Watch
Comment on recently published papers written by the medical editors of Glycosmedia.

Diabetes Updates
Updates written by Professor Steve Bain (Diabetologist) and Dr. Mark Freeman (Diabetologist).

Book and Product Reviews
A selection of book and product reviews written by the contributing editors of Glycosmedia.
The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Glycosmedia complies with the HONcode standard for trustworthy health information: verify here.


Copyright © 2021 Glycosmedia Partnership

Our mailing address is:
Glycosmedia
9 Woodburn Drive
West Cross
Swansea, West Glamorgan SA3 5TZ
United Kingdom

Add us to your address book


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp